Toward a Modern Synthesis of Immunity: Charles A. Janeway Jr. and the Immunologist’s Dirty Little Secret by Gayed, Peter M.
131
YALE JouRNAL of BioLoGY AND MEDiCiNE 84 (2011), pp.131-138.
Copyright ﾩ 2011.
foCuS: YALE SCHooL of MEDiCiNE BiCENTENNiAL
toward a Modern synthesis of immunity:
Charles a. Janeway Jr. and the immunologist’s
dirty little secret
Peter M. Gayed
MD and PhD candidate, Immunobiology Department, Yale School of Medicine, New
Haven, Connecticut
This essay chronicles the major theoretical and experimental contributions made by Charles
A. Janeway, Jr. (1943-2003), Howard Hughes Medical institute investigator and Yale Pro-
fessor of immunobiology, who established the fundamental role of the innate immune sys-
tem in the induction of the adaptive arm.  
Charles Alderson Janeway, Jr., (1943-
2003) did not like secrets. Indeed, as a Yale
professor and scientist, it was his goal to
shed light on the “immunologist’s dirty lit-
tle secret” [1], that is, that foreign antigen
alone was insufficient to elicit the adaptive
immune response and that scientists instead
had to routinely pepper their experiments
with crude extracts like mineral oil, my-
cobacteria,  and  aluminum  hydroxide  in
order to get T and B cells to do their bid-
ding. If lymphocytes were the discerning
finger that identified self from non-self,
why was it that non-self antigens alone
failed to be recognized? What role did these
crude substances, euphemistically termed
“adjuvants,” play in the initiation of the
body’s immune response? And why did
they appear to be required for the produc-
tion of activated T and B cells? Janeway
decided to find out.
Janeway’s early years and
training
Janeway’s loyalty to what we now call
the adaptive immune system might have
begun when he developed measles as a
young boy. Janeway’s father was an emi-
nent Harvard pediatrician, researcher, and
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Boston. At the time, Janeway Sr. was ad-
ministering pooled immunoglobulins for the
treatment of agammaglobulinemia, a condi-
tion of antibody deficiency, as well as for the
prevention  of  measles.  As  Janeway  de-
scribes it, his father “lined up all the kids in
the  neighborhood,  injected  them  with
gamma globulin, and then systematically ex-
posed each of them to me” [2]. As the young
Janeway would learn (and as his father re-
ported in a 1944 issue of the Journal of Clin-
ical  Investigation),  this  measure  would
reduce the likelihood of measles transmis-
sion shortly after treatment but not provide
long-lasting immunity [3].
As a Harvard medical student, Janeway
would be reacquainted with the particulars of
antibodies  in  the  laboratory  of  J.H.
Humphrey at the National Institute for Med-
ical Research, London, England, where he
spent two years. There, he studied the anti-
body response to injections of two enan-
tiomers of a synthetic tripeptide known as
TGA. Janeway found that antibodies pro-
duced in response to D-TGA did not cross-
react with L-TGA and vice-versa, supporting
the idea that an antibody binds to its antigen
with specificity. Later, he would devise a red
blood cell-marking technique to show that
antibodies  against  blood  type A  antigens
would exclusively crosslink type A red blood
cells in a mixture of type A and B blood.
Such novelty afforded him another English
sabbatical,  this  time  at  the  University  of
Cambridge with Robin Coombs, a noted im-
munologist and inventor of the clinical test
that bears his name.
In 1977, after a postdoctoral fellowship
at the NIH Laboratory of Immunology and
further training at the Uppsala Biomedical
Center, Sweden, Janeway began his profes-
sorship at Yale in the Department of Pathol-
ogy’s  Division  of  Immunology,  which
would later become one of the first free-
standing immunology sections in the United
States, in large part due to efforts led by
Janeway himself.
At the helm of his own lab, Janeway
began steering toward unaddressed ques-
tions concerning the adaptive system he had
come to know so well. At the time, there
were examples of immune responses that
could occur in the partial or complete ab-
sence of an adaptive system. The activation
of macrophages without T cell help, the ini-
tiation of the complement system independ-
ent of antibody (the so-called “alternative
pathway”), the ability to generate an anti-
body response in the absence of what was
thought to be a required T cell population —
all this was evidence against a conventional
view that T and B cells were necessary and
sufficient to launch a response against anti-
gen. This, along with the “immunologist’s
dirty little secret,” goaded Janeway into a
line of inquiry that would bring to the fore of
immunological research an often ignored
corner: the innate immune system.
theoretiCal insights and the
two-signal hypothesis
Previous to 1989, immunologists be-
lieved that the immune system, effectively
defined by T and B cells, could recognize,
attack, and clear whatever stimulus had ac-
tivated it. Researchers could drive the ex-
pansion of T cells or antibody-secreting B
cells with any antigen — provided they fol-
lowed the immunologist’s cookbook. What
fixated Janeway was the ubiquitous call for
adjuvant in each recipe, an almost alchemic
mixture of mycobacterial components or
alum with killed Bordetella.
In a lucid essay [4] he co-authored with
his now most famous postdoctoral fellow,
Ruslan Medzhitov, Janeway explains why
the adaptive system’s response against anti-
gen would require an additional signal in the
form of adjuvant. The conversion of T and B
cells into formidable destroyers, he explains,
must rely on a separate system of cells and
receptors. This is because the binding do-
main of the T and B cell receptors (TCRs
and  BCRs†)  that  recognize  antigen  are
formed randomly during lymphocytic de-
velopment. This randomness endows our
adaptive immune system with the ability to
respond to never-before-seen pathogens, but
it also means that T and B cells can form re-
ceptors against self proteins and thus medi-
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Janeway  offered  this  theoretical  enigma:
How can a receptor with a randomly gener-
ated ligand-binding site but a constant sig-
naling  domain  convey  meaningful
information? In other words, how is it that a
lymphocyte “knows” when to proliferate
and attack, and when not to, if antigen alone
is the sole conveyor of information? Ac-
cording to Janeway, antigen could not be the
sole conveyor. The adaptive system, he rea-
soned, must rely on other receptors that are
not randomly generated — that is, it must
rely on interactions that would have been se-
lected  over  evolutionary  time.  His  first
hunch about these interactions, which was
to birth a frenzy of discoveries continuing
today, was that they had something to do
with microbes.
Just prior to Janeway’s start at Yale in
1977, a theoretical paper was published by
two Australian immunologists regarding the
immune response observed following trans-
plantation. The rejection of transplanted tis-
sue  was  explained  by  the  presence  of
“histocompatibility molecules,” which were
believed to be any number of non-self anti-
gens carried by the graft. These antigens
would be recognized and attacked by the
host’s T or B cells. The sequitur of this con-
cept would be that the greater the unrelated-
ness between donor and recipient, the more
abundant the antigens and the greater the im-
mune response. However, it became clear
that reactivity was more vigorous “between
different strains within a species than be-
tween species” [5]. Additional observations
led the authors to hypothesize that in addi-
tion to antigen, a “species-specific . . . signal
passes  between  the  [immune  and  trans-
planted] cells,” thus accounting for the more
pronounced response observed when donor
and recipient were of the same species.
Experimental evidence for the existence
of this “second signal” would not come until
1987, when two American immunologists at
the  NIH  showed  that  antigen  presenting
cells (APCs) displaying a fragment of pi-
geon cytochrome c could not drive the ex-
pected proliferation of T cells (specific to
this fragment) if the APCs were pre-treated
with a cross-linking agent known as ECDI
[6]. After additional experiments confirmed
that ECDI treatment did not modify the anti-
gen itself or the surface molecules display-
ing the antigen, the authors concluded that
ECDI “inactivated an accessory function of
the APC.” Such was the first experimental
suggestion that antigen alone was necessary
but not sufficient to drive the adaptive re-
sponse. The “accessory function” provided
by APCs appeared not to be so accessory.
Rather, it appeared this second signal was
crucial for activation of T cells.
Similar requirements seemed to exist in
B cells, where the addition of antigen plus
the Gram-negative membrane component
lipopolysaccharide (LPS), but not antigen
alone, could induce antibodies [7]. Hence,
LPS became known as a “non-antigen” B
cell mitogen because it activated B cells and
drove their proliferation without triggering
an antibody response to itself.
In the same period, there were many
groups interested in the microbial defense
strategies used by innate cells such as neu-
trophils and macrophages [8]. Indeed, there
was a growing list of effector mechanisms
that included phagocytosis, cell degranula-
tion, and lytic peptides, all contributing to
efficient  clearance  of  pathogens. As  one
might expect, these arms could be induced
by a variety of microbial products, includ-
ing LPS. 
evolution of iMMunity: More
than self vs. non-self
Despite the parallels, no formal theory
had satisfactorily reconciled the two-signal
hypothesis with the increasingly visible role
of microbial components in the activation of
both the innate and adaptive arms. In his in-
troduction to the 1989 Cold Spring Harbor
Symposium, Janeway would articulate such
a theory [1]. In it he explains how early and
important  studies  by  Karl  Landsteiner,
which demonstrated that proteins could be
modified chemically to induce antibody for-
mation [9], ingrained in immunologists the
misperception that all “foreign macromole-
cules are equally able to give rise to an im-
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today, Janeway proposed what was then an
unorthodox belief that the immune system
evolved not simply to discriminate self from
non-self, but “noninfectious self from infec-
tious non-self.” In other words, that the im-
mune system evolved against, and thus for
its induction depended on, the presence of
microbes.
He further implicated that it was the in-
nate arm that was responsible for this dis-
crimination  and  that  invariant,
germline-encoded receptors on innate cells
—as opposed to the randomly generated
BCRs and TCRs expressed by B and T cells
—  would  recognize  conserved  microbial
patterns. Support for this idea came from
growing evidence that the invertebrate king-
dom lacks any sign of an adaptive system
and yet is able to mount immune responses
against natural pathogens. Thus it appeared
likely that a system to identify “self from
non-self” had developed early in evolution-
ary history, far before the arrival of lympho-
cytes. 
By  1990,  Janeway  knew  he  had  to
prove two things experimentally: that mi-
crobial components were recognized by in-
nate  cells  and  that  this  recognition  was
transmitted as the “second signal” required
for lymphocyte activation. In a remarkable
series of discoveries over the next decade,
Janeway  and  others  would  confirm  the
tenets of his theory.
antigen is neCessary but not
suffiCient for adaptive 
induCtion
In 1991, Janeway and postdoctoral fel-
low Yang Liu used an in vitro model to in-
vestigate the role of LPS in the induction of
T cell activation [10]. In this model, anti-
CD3 monoclonal antibody (anti-CD3 mAb)
was used to crosslink, cluster, and thus acti-
vate the TCRs of a resting T cell, mimick-
ing the action of a specific antigen.
Analogous  to  conditions  of  antigen
alone, the presence of anti-CD3 mAb alone
could not drive T cell proliferation. How-
ever, when the experiment was repeated in
the presence of splenocytes (a heterogenous
cell population derived from the spleen), the
T  cells  showed  marked  proliferation. To
identify the cell providing the second or
what then began to be dubbed the “co-stim-
ulatory” signal, Janeway and Liu sorted the
splenocytes into their constituent parts and
repeated the experiment. Consistent with
earlier studies in lymph nodes [11-13], it
was the B cell compartment that accounted
for the observed T cell response. 
This was an unusual but not entirely
surprising find. It was known that B cells
contributed to the T cell response by pre-
senting antigen, but Janeway was using a
system in which signal 1 was provided by
an “antigen-independent” stimulus, i.e., the
anti-CD3 mAb. Moreover, the B cells them-
selves had not been provoked with any par-
ticular antigen. It appeared as if B cells were
offering a signal that had nothing to do with
their own unique antigen specificity. To be
sure, the researchers repeated their experi-
ment  after  adding  antibodies  that  would
make  the  BCRs  physically  inaccessible.
Still, the B cells were able to promote the T
cell response. Thus, co-stimulation was pro-
vided by a “non-specific” molecule carried
by all B cells. 
Importantly,  the  researchers  also
showed that this signal was not constitu-
tively active but inducible on B cells after
their treatment with LPS. That is, purified B
cells were not able to support T cell prolif-
eration unless they first received LPS. The
same was observed when macrophages, a
cell type belonging to the innate system
proper, were used in place of B cells: Only
pre-treatment of macrophages with LPS or
zymosan  (an  established,  yeast-derived
macrophage activator) could induce robust
T cell proliferation in the presence of anti-
CD3 mAb.
Thus, Janeway, supported by studies
from independent groups, had demonstrated
that antigen alone was insufficient to trigger
the adaptive system. A second signal, which
could  be  provided  by  B  cells  or
macrophages, was required — and, criti-
cally, this signal was only made available
after treatment with microbial products such
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that the second signal, in this case, was pro-
vided by two closely related members of the
immunoglobulin  gene  superfamily,  B7.1
(CD80) and B7.2 (CD86)1. The B7 mole-
cules are expressed by B cells, macrophages,
and dendritic cells — collectively known as
the antigen presenting cells of the immune
system — but only after their exposure to
microbial products (Figures 1 and 2). Thus,
the first of Janeway’s two-part theory on the
induction  of  the  adaptive  arm  had  been
borne out. Not yet identified, however, was
the receptor by which microbial products
were  recognized.  Impressively,  this,  too,
would come from the Janeway lab.
Because  macrophages  and  dendritic
cells had been shown to be the most potent
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1Working with Richard flavell, Janeway later implicated co-stimulatory molecules in the pathogenesis
of autoimmune disease. in one study, pancreatic ʲ-cells were modified such that they expressed the
B7.1 molecule. in a mouse line genetically susceptible to diabetes, expression of B7.1 resulted in ear-
lier and more extensive pancreatic disease [14]. in another study, the presence of CD40 ligand (CD40L)
was essential for the expression of B7 molecules in an autoimmune multiple sclerosis-like disease model
in mice. The absence of CD40L thus precluded the development of disease, despite immunization with
the triggering antigen (myelin basic protein) in freund’s adjuvant [15].
figure 2. Top panel:
Note that lone en-
gagement of co-stim-
ulatory molecules
(signal 2) has no ef-
fect on a T cell. Bot-
tom panel: on the
other hand, recogni-
tion of antigen (signal
1) in the absence of
co-stimulatory mole-
cules — as might
occur in vivo when
autoreactive T cells
bind to self antigens
— results in “anergy,”
a permanent state of
unresponiveness
which disables the T
cell’s ability to mount
an immune attack.
Anergy is one mecha-
nism by which au-
toimmunity is
avoided.
figure 1. Simultaneous engagement of the
TCR with its cognate antigen (red circle)
and of the B7 molecule with its receptor
(CD28) respectively provide the first and
second signals required for T cell activa-
tion.T cell-activating APCs, Janeway’s lab initi-
ated a hunt for molecules expressed on the
surface of these cells that were capable of
both binding microbial products and induc-
ing the expression of CD80 and CD86. Such
receptors  would  provide  the  mechanistic
basis for adaptive induction by the innate
system.
the Case for fruit flies in
huMan iMMunity
By the mid-1990s, the transcriptional
factor NF-κB had been established as the
critical  activator  of  innate  immune  cells
[16]. It was also known that the NF-κB sig-
naling pathway was activated by transmem-
brane receptors that bore a cytosolic domain
known as TIR [8]. Working as a postdoctoral
fellow in the Janeway lab, Ruslan Medzhi-
tov screened a human splenic cDNA library
for genes containing TIR domains. A gene
was identified, but instead of an extracellu-
lar domain related to other known microbial
receptors of the innate system, it contained a
leucine-rich repeat (LRR) domain. This was
an unexpected find. The LRR domain be-
longed  to  a  family  of  proteins  found  in
Drosophila [17], among them a receptor
called Toll, itself involved in the dorsal-ven-
tral patterning of developing flies. 
It  was  enigmatic  that  a  receptor  in-
volved  in  Drosophila axis  development
would contain a cytosolic inflammation-re-
lated motif such as TIR. However, in the
summer of that same year, an independent
group  working  from  Strasbourg,  France,
demonstrated  that  loss-of-function  muta-
tions  in  the Toll  receptor  left  adult  flies
highly susceptible to fungal infection and
death [18]. They also demonstrated that Toll
gain-of-function mutations led to the consti-
tutive expression of critical antifungal genes.
Moreover,  the  downstream  pathways  on
which Toll relied were homologous to the
mammalian pathways that activated NF-κB
via TIR domains. Thus it appeared that in
addition  to  its  patterning  function  in
Drosophila embryos, Toll mediated critical
immune responses in the adult fly (Figure
3).
These findings galvanized the Janeway
laboratory, which had already observed that
a constitutively activated form of the gene
identified by Medzhitov potently activated
NF-κB, released a variety of pro-inflamma-
tory  cytokines,  and,  importantly  for
Janeway’s theory, upregulated the expres-
sion of the co-stimulatory molecule CD80
in  human  cell  lines  [8].  Janeway  and
Medzhitov would later publish this finding
in a 1997 issue of the journal Nature [19].
ConClusion: the iMMune 
systeM, revised
The tenets of Janeway’s theory were
made complete when Godowski and col-
leagues showed that a human homologue of
the Toll receptor recognized LPS and initi-
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figure 3. scanning
electron micro-
graph of a toll-defi-
cient adult fly with
fatal fungal infec-
tion. The dorsal tho-
rax is blanketed by
germinating As-
pergillus hyphae.
image from Lemaitre
et al [18].ated the critical NF-κB signaling pathway
[20].  In  that  same  period,  a  number  of
human receptors with Toll homology were
identified [21,22], which collectively came
to be known as the Toll-like receptor (TLR)
family. To date, 12 mouse and 10 human
TLRs have been identified, each recogniz-
ing a unique but conserved microbial pattern
and each capable of upregulating co-stimu-
latory molecules among antigen presenting
cells (Table 1).
In just 10 years, Janeway and his col-
leagues exposed the immunologist’s dirty little
secret. In doing so, they revised the working
model of the immune system. It is now clear
that antigen presenting cells recognize con-
served  microbial  components,  collectively
dubbed PAMPs for “pathogen-associated mo-
lecular patterns.” These PAMPs serve as lig-
ands for a broad class of proteins referred to as
pattern recognition receptors (PRRs), of which
the TLRs are a subset. When a PRR on an APC
binds to its corresponding PAMP, the cell be-
gins to efficiently present antigen (signal 1),
upregulate the expression of co-stimulatory
molecules (signal 2), and elaborate cytokines
(now known as “signal 3”) that guide the for-
mation of adaptive cells uniquely poised to re-
spond  to  the  inciting  pathogen.  Thus,  the
adaptive system is mobilized against antigens
in the context of infection, and this defense is
specifically targeted to niches the pathogen
calls home.
In addition to advancing the basic sci-
ence of immunology, Janeway’s revelation
on induction of the adaptive system has had
important clinical implications, spurring an
era of rational vaccine design that exploits
PRRs. Immunologists today recognize that
effective  vaccines  will  stimulate  APCs.
Known PRRs, like those within the TLR
family, are specifically being triggered by
adding or conjugating PAMPs to antigens of
interest. For example, peptidoglycans and
other skeletal cell wall components in the
Bacillus Calmette-Gu￩rin (BCG) vaccine
are recognized by TLR2 and TLR4 to gen-
erate protective immunity against Mycobac-
terium tuberculosis [23]. Similarly, vaccines
against Haemophilus influenzae type b, once
a leading cause childhood meningitis, can be
conjugated with outer-membrane proteins
from Neisseria to elicit effective adaptive re-
sponses, a phenomenon dependent on TLR2
[24]. Moreover, the adjuvant properties of
recently developed DNA vaccines, which
contain  unmethylated  CpG  clusters,  are
thought to be mediated by TLR9 [25]. 
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toll-like receptor
TLR-1:TLR-2 heterodimer
TLR-2:TLR-6 heterodimer
TLR-3
TLR-4
TLR-5
TLR-7
TLR-8
TLR-9
TLR-10
ligand
Triacyl lipopeptides
Diacyl lipopeptides
Double-stranded RNA
Lipopolysaccharides
flagellin
Single-stranded RNA
G-rich oligonucleotides
unmethylated CpG DNA
unknown
table 1. the family of toll-like receptors and their ligands in the human.
All TLRs are thought to act as homodimers, unless otherwise specified. Table adapted from
Janeway’s Immunobiology, Seventh Edition [26].Janeway was of that rare breed of sci-
entists whose theoretical contributions are as
well-known as their experimental ones. In
his lifetime, he contributed to more than 290
publications, but his ideas undoubtedly in-
fluenced and informed many fold more. The
field of immunology continues to benefit
from his legacy.
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